Potential of Beta-Hydroxybutyrate (BHB) in the Management of Type 2 Diabetes and Risk of Ketoacidosis in Diabetic Patients
Article Sidebar
Main Article Content
Page: 562-570
Abstract
Diabetes mellitus (DM) is a metabolic disease with an increasing prevalence every year, especially type 2 DM. Before insulin as a DM therapy, the ketogenic diet was known as the main nonpharmacological therapy, which is a high-fat, adequate-protein, and low-carbohydrate intake diet. A ketogenic diet causes the ketogenesis process and produces ketone bodies, one of which is beta-hydroxybutyrate (BHB) which has various therapeutic effects such as lowering blood sugar levels. This study is a narrative review compiled by searching the literature on Google Scholar and PubMed databases with keywords related to the research topic. Bibliometric analysis was also carried out with VOSviewer software to determine the keywords relevant to the research topic. The results of the reviews that have been carried out show that BHB has the potential as a therapeutic agent in patients with DM2 with various mechanisms of action in lowering blood sugar levels including increased insulin secretion, suppression of lipolysis, and decreased Ala release. BHB as a supplement has been widely studied for its therapeutic effects but it is necessary to pay attention to the side effects that can occur such as ketoacidosis.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes. 2018;42:S10–5. DOI: https://doi.org/10.1016/j.jcjd.2017.10.003
International Diabetes Federation. IDF Diabetes Atlas. Seventh edition. Belgium: International Diabetes Federation; 2015.
Hardianto D. Telaah komprehensif diabetes melitus: klasifikasi, gejala, diagnosis, pencegahan, dan pengobatan. Jurnal bioteknologi dan biosains Indonesia. 2020;7(2):304-17. DOI: https://doi.org/10.29122/jbbi.v7i2.4209
Choi YJ, Jeon SM, Shin S. Impact of a ketogenic diet on metabolic parameters in patients with obesity or overweight and with or without type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrients. 2020;12(7):1–19. DOI: https://doi.org/10.3390/nu12072005
Joshi S, Ostfeld RJ, McMacken M. The Ketogenic Diet for Obesity and Diabetes - Enthusiasm Outpaces Evidence. Vol. 179, JAMA Internal Medicine. American Medical Association; 2019. p. 1163–4. DOI: https://doi.org/10.1001/jamainternmed.2019.2633
Gotera W, Sugitha KS. Manfaat Diet Ketogenik pada Tata Laksana Obesitas. Cermin Dunia Kedokteran. 2023;50(8):451-8. DOI: https://doi.org/10.55175/cdk.v50i8.651
Ayuningtyas R, Gz M. The Ketogenic Diet and Its Impact on The Gut Microbiota In Diabetes Mellitus Type 2. J Gizi dan Kesehatan. 2021;13(1). DOI: https://doi.org/10.35473/jgk.v13i1.98
Brouns F. Overweight and diabetes prevention: is a low-carbohydrate–high-fat diet recommendable?. European journal of nutrition. 2018;57(4):1301-12. DOI: https://doi.org/10.1007/s00394-018-1636-y
Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer–where do we stand?. Molecular metabolism. 2020;33:102-21. DOI: https://doi.org/10.1016/j.molmet.2019.06.026
Drabińska N, Wiczkowski W, Piskuła MK. Recent advances in the application of a ketogenic diet for obesity management. Trends in Food Science & Technology. 2021 Apr 1;110:28-38.. DOI: https://doi.org/10.1016/j.tifs.2021.01.080
Kolb H, Kempf K, Röhling M, Lenzen-Schulte M, Schloot NC, Martin S. Ketone bodies: from enemy to friend and guardian angel. BMC medicine. 2021;19:1-5. DOI: https://doi.org/10.1186/s12916-021-02185-0
Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of exogenous ketone supplementation on blood glucose: a systematic review and meta-analysis. Advances in Nutrition. 2022;13(5):1697-714. DOI: https://doi.org/10.1093/advances/nmac036
Sudarjat H. Computing bibliometric analysis with mapping visualization using vosviewer on “pharmacy” and “special needs” research Data in 2017-2021. ASEAN Journal of Community and Special Needs Education. 2023;2(1):1-8.
Afriliana M, Yuniarti E. Analisis Bibliometrik Respon Imun Pada Penyakit Leukemia Melalui Aplikasi Vosviewer. Jurnal Pendidikan Tambusai. 2024;8(2):17248-56.
Chisholm-Burns MA, Malone PM, Schwinghammer TL, Kolesar JM, Wells BG, DiPiro JT. Pharmacotherapy principles & practice. Sixth edition. United States: McGraw-Hill Education; 2012.
Deepthi B, Sowjanya K, Lidiya B, Bhargavi RS, Babu PS. A modern review of diabetes mellitus: an annihilatory metabolic disorder. J In Silico In Vitro Pharmacol. 2017;3(1).
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020;21(17):6275. DOI: https://doi.org/10.3390/ijms21176275
Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. Diabetes research and clinical practice. 2014;106(2):173-81. DOI: https://doi.org/10.1016/j.diabres.2014.08.009
Falkenhain K, Oliveira BF, Islam H, Neudorf H, Cen HH, Johnson JD, Madden K, Singer J, Walsh JJ, Little JP. The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials. American Journal of Physiology-Endocrinology and Metabolism. 2024;326(1):E61-72. DOI: https://doi.org/10.1152/ajpendo.00332.2023
Soto‐Mota A, Norwitz NG, Evans RD, Clarke K. Exogenous d‐β‐hydroxybutyrate lowers blood glucose in part by decreasing the availability of L‐alanine for gluconeogenesis. Endocrinology, Diabetes & Metabolism. 2022;5(1):e00300. DOI: https://doi.org/10.1002/edm2.300
Pan A, Sun XM, Huang FQ, Liu JF, Cai YY, Wu X, Alolga RN, Li P, Liu BL, Liu Q, Qi LW. The mitochondrial β-oxidation enzyme HADHA restrains hepatic glucagon response by promoting β-hydroxybutyrate production. Nature Communications. 2022;13(1):386. DOI: https://doi.org/10.1038/s41467-022-28044-x
Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016;125:259-66. DOI: https://doi.org/10.1016/j.biochi.2015.10.024
Adachi Y, De Sousa-Coelho AL, Harata I, Aoun C, Weimer S, Shi XU, Herrera KN, Takahashi H, Doherty C, Noguchi Y, Goodyear LJ. l-Alanine activates hepatic AMP-activated protein kinase and modulates systemic glucose metabolism. Molecular metabolism. 2018;17:61-70. DOI: https://doi.org/10.1016/j.molmet.2018.08.002
Saputra DH. Peran Diet Ketogenik dalam Tata Laksana Epilepsi. Cermin Dunia Kedokteran. 2022;49(11):629-34. DOI: https://doi.org/10.55175/cdk.v49i11.318
Myette-Côté É, Caldwell HG, Ainslie PN, Clarke K, Little JP. A ketone monoester drink reduces the glycemic response to an oral glucose challenge in individuals with obesity: A randomized trial. American Journal of Clinical Nutrition. 2019;110(6):1491–501. DOI: https://doi.org/10.1093/ajcn/nqz232
Riani R, Muzakir M, Nislawati N, Tania B. Sosialisasi Tindakan Pencegahan Kondisi Kritis Dari Diabetes Mellitus Tipe II. Dedikasi: Jurnal Pengabdian Pendidikan dan Teknologi Masyarakat. 2024;2(1):01-4. DOI: https://doi.org/10.31004/dedikasi.v2i1.25
Miarta A, Zulfariansyah A. Tatalaksana Pasien Ketoasidosis Diabetikum yang Disertai Syok Sepsis. Majalah Anestesia & Critical Care. 2019;37(3):90-6.
Ahlström S, Ahlner J, Jönsson AK, Green H. The Importance of BHB Testing on the Post-Mortem Diagnosis of Ketoacidosis. Biomolecules. 2021;12(1):9. DOI: https://doi.org/10.3390/biom12010009